Article Versions Notes

Boziki M, Bakirtzis C, Sintila S-A, Kesidou E, Gounari E, Ioakimidou A, Tsavdaridou V, Skoura L, Fylaktou A, Nikolaidou V, et al. Ocrelizumab in Patients with Active Primary Progressive Multiple Sclerosis: Clinical Outcomes and Immune Markers of Treatment Response. Cells. 2022; 11(12):1959. https://doi.org/10.3390/cells11121959

Boziki, Marina, Christos Bakirtzis, Styliani-Aggeliki Sintila, Evangelia Kesidou, Evdoxia Gounari, Aliki Ioakimidou, Vasiliki Tsavdaridou, Lemonia Skoura, Asimina Fylaktou, Vasiliki Nikolaidou, and et al. 2022. "Ocrelizumab in Patients with Active Primary Progressive Multiple Sclerosis: Clinical Outcomes and Immune Markers of Treatment Response" Cells 11, no. 12: 1959. https://doi.org/10.3390/cells11121959

Boziki, M., Bakirtzis, C., Sintila, S. -A., Kesidou, E., Gounari, E., Ioakimidou, A., Tsavdaridou, V., Skoura, L., Fylaktou, A., Nikolaidou, V., Stangou, M., Nikolaidis, I., Giantzi, V., Karafoulidou, E., Theotokis, P., & Grigoriadis, N. (2022). Ocrelizumab in Patients with Active Primary Progressive Multiple Sclerosis: Clinical Outcomes and Immune Markers of Treatment Response. Cells, 11(12), 1959. https://doi.org/10.3390/cells11121959